Tag
Pharmaceuticals
68 articles
Pharmaceutical companies are demonstrating varied performance and strategic shifts. Viyash Scientific reported a robust 16.2% year-over-year revenue increase in Q2 FY27, alongside significant debt reduction and ambitious R&D plans for its companion animal segment. Meanwhile, Dishman Carbogen Amcis posted a substantial net loss in H1 FY27 due to lower CDMO revenue, though it completed a successful FDA inspection and initiated tech transfers. Elsewhere, Sai Parenterals expanded its domestic presence through the acquisition of Bion Therapeutics, while Balaxi Pharmaceuticals reported a remarkable 450% surge in Q2 PAT, driven by operational improvements and strategic expansions. These developments highlight a dynamic landscape within the sector, with companies navigating challenges and pursuing growth opportunities through innovation, acquisitions, and strategic investments.
Bhagwati Medical Hall Licences Restored, Contempt Dismissed
Supreme Court heard contempt petitions (Nos. 747‑748/2025) filed by Bhagwati Medical Hall against Shashi Mohan Gupta and others.
Compliance affidavit dated 05‑Nov‑2026 confirmed approval of drug licen
Orchid Pharma Q2 FY27 Earnings Call Recording
Orchid Pharma uploaded the audio recording of its Q2 FY27 earnings call held on November 17, 2026.
The call discussed unaudited limited reviewed standalone and consolidated results for the quarter end
Novelix Pharmaceuticals Opens Hyderabad Corporate Office
Novelix Pharmaceuticals intimates BSE of opening a new corporate office in Hyderabad effective 16th November 2026.
Disclosure is made pursuant to SEBI Listing Regulations Regulation 30 following a boa
Viyash Scientific Q2 FY27 Revenue Up 16.2% YoY
Viyash Scientific reported Q2 FY27 revenue of INR 988 crores, up 16.2% YoY, with PAT at INR 85 crores.
The company completed the acquisition of BioForLife Italia, effective October 1, 2026, to be cons
Fabtech Cleanrooms October Order Book Hits ₹27.75 Crore
Fabtech Cleanrooms reported ₹27.75 crore in consolidated orders for October 2026, led by Pharma (₹16.98 crore) and Renewable Energy (₹4.99 crore).
The company's total order book stands at ₹468.50 cror
Chemkart Invests ₹2.59 Cr in Subsidiary Rights Issue
Chemkart India invested ₹2.59 crore in its wholly-owned subsidiary Easy Raw Materials via a rights issue of 485,000 shares at ₹53.50 per share.
The investment utilizes IPO proceeds for commissioning t
AstraZeneca Signs LOI with Strand Life Sciences
AstraZeneca India signed a Letter of Intent with Reliance subsidiary Strand Life Sciences to explore healthcare collaboration opportunities.
The companies confirmed they are not related parties and th
GSK Pharma Seeks Shareholder Approval for ₹630 Crore RPT
GSK Pharmaceuticals seeks shareholder approval via postal ballot for related party transactions worth up to ₹630 crore with GSK Biological S.A. for FY 2026-27.
E-voting period runs from November 18 to
AstraZeneca India Signs LOI with Strand Life Sciences
AstraZeneca India signed a Letter of Intent with Strand Life Sciences to explore healthcare collaboration opportunities in India.
The companies confirmed they are not related parties and the LOI does
Sai Parenterals Subsidiary Acquires Bion Therapeutics Majority Stake
Sai Parenterals' subsidiary SP Analytics acquires majority stake in Bion Therapeutics' prescription business via all-cash deal.
Acquisition adds 16 established brands, 250 field staff, and access to 2
Parmax Pharma Q2 Net Profit at ₹1.73 Lakh
Parmax Pharma reported Q2 FY27 standalone net profit of ₹1.73 lakh, a significant improvement from a ₹2.08 crore loss in Q2 FY26.
Revenue from operations surged 362% YoY to ₹11.70 crore in Q2 FY26, dr
Arvaya Healthcare Q2 Earnings Call Recording Available
• Arvaya Healthcare submitted an audio recording of its Q2 FY2026 earnings call to BSE per SEBI Regulation 30.
• The investor conference call was held on November 16, 2026, to discuss operational and
Dishman Carbogen Amcis Q2 Earnings Call Recording
• Dishman Carbogen Amcis disclosed audio recording of its Q2 FY2026-27 investor conference call held on 16th November 2026.
• The call discussed financial results and performance for the quarter and h
Corona Remedies November 20 JP Morgan Investor Meeting
Corona Remedies officials will attend a virtual group investor meeting organized by J.P. Morgan on November 20, 2026.
Discussions will be based solely on publicly available information with no unpubli
Mahamaya Lifesciences H1FY27 Earnings Call Schedule
Mahamaya Lifesciences schedules H1FY27 earnings call for November 19, 2026, at 4:00 PM IST.
Call will feature Chairman, Managing Director, Whole Time Director, and CFO as speakers.
Disclosure made und
FDC Limited ₹120 Crore Equity Share Buyback
FDC Limited announces a tender offer buyback of 24 lakh equity shares at ₹500 per share for an aggregate ₹120 crore.
The buyback represents 4.84% of standalone net worth and offers a 45.58% premium to
Dishman Carbogen H1FY27 Net Loss ₹1246 Crore
Dishman Carbogen reported a consolidated net loss of ₹1,246.1 mn for H1FY27, a 240.5% YoY decline, on revenue of ₹11,850.1 mn.
EBITDA margin contracted sharply to 8.9% in H1FY27 from 21.3% YoY due to
Lupin Seeks Shareholder Approval for Akhil Gupta Director Appointment
Lupin Limited issues a postal ballot notice seeking shareholder approval via remote e-voting for the appointment of Mr. Akhil Gupta as an Independent Director.
The special resolution proposes a five-y
Balaxi Pharmaceuticals Q2 PAT Surges 450% YoY
• Investor presentation details Q2 FY27 consolidated PAT surge of 450% YoY to ₹115.02 lakhs on revenue growth of 39.44%.
• Highlights operational commencement of Jadcherla formulation facility and add
Suven Life Sciences Presents Alzheimer's Drug Data at CTAD
Suven Life Sciences will present Phase-3 baseline data for Masupirdine and Phase-1 safety data for Tenaclidine at the CTAD-2026 conference in Boston.
Masupirdine Phase-3 study enrollment is complete w
Suven Life Sciences Presents Alzheimer's Drug Data at CTAD-2026
Suven Life Sciences will present Phase-3 baseline data for Masupirdine and Phase-1 safety data for Tenaclidine at the CTAD-2026 conference in Boston.
Masupirdine Phase-3 study targeting agitation in A
Vineet Laboratories Q2 FY27 Financial Results
Vineet Laboratories reported Q2 FY27 revenue of ₹14.18 crore, down 18.6% YoY from ₹17.42 crore.
Net profit after tax stood at ₹1.16 lakh for the quarter, significantly lower than ₹4.01 lakh in Q2 FY26
Valiant Laboratories Promoter Group Member Demise
Valiant Laboratories intimates the demise of promoter group member Chandrakant Vallabhaji Gogri on November 15, 2026.
Gogri played a pivotal role in the company's growth and development over the years
Natural Capsules Q2 Revenue Up 12% YoY
Natural Capsules reported Q2FY27 consolidated revenue of ₹51.15 Cr, up 12% YoY, with EBITDA at ₹3.01 Cr showing 440% YoY improvement.
The company strategically converted idle HPMC lines to gelatine pr
Natural Capsules Q2 Net Loss at ₹4.22 Crore
Natural Capsules reported Q2FY27 unaudited results with ₹51.15 crore revenue but ₹4.22 crore net loss.
Company converted idle HPMC lines to gelatine, driving volume growth and maintaining improved rea
ANG Lifesciences Q2 FY27 Net Loss ₹2.66 Crore
Board approved Q2 FY27 unaudited standalone net loss of ₹2.66 crore and consolidated net loss of ₹2.09 crore for the quarter.
Appointed Mrs. Preeti Sarin as Additional Independent Director for a five-
Alembic Pharma USFDA Binimetinib Final Approval
Alembic Pharmaceuticals received USFDA final approval for its generic Binimetinib Tablets, 15 mg and 45 mg.
The product has an estimated market size of US$282 million and the company is eligible for 1
Astonea Labs Reports No IPO Fund Deviation H1 2026
Astonea Labs Limited filed a regulatory disclosure confirming no deviation or variation in IPO fund utilization for the half-year ended 30th September 2026.
Total IPO proceeds raised were ₹37.665 cror
Gufic Biosciences Q2 FY27 PAT Rises 58% YoY
Gufic Biosciences reported Q2 FY27 revenue of ₹288.4 crore and PAT of ₹23.5 crore, representing 25% YoY revenue growth and 58% YoY PAT growth.
The company made significant progress with its Indore fac
Natural Capsules Q2 & H1 FY27 Earnings Call Schedule
Natural Capsules schedules investor call on Nov 19, 2026, to discuss Q2 & H1 FY27 unaudited financial results.
Management participants include Managing Director Sunil Mundra and CFO Raj Kishore Prasad
Astonea Labs H1 FY27 Revenue Up 44.6% YoY
Astonea Labs reported unaudited H1 FY27 consolidated revenue of ₹95.86 crore, up 44.6% YoY, with PAT surging 153.3% to ₹4.82 crore.
The Board approved financial results, a ₹12 crore related party tran
Gufic Biosciences Q2 Net Profit Rises 57% YoY
Gufic Biosciences reported Q2 FY27 standalone net profit of ₹234.89 lakh, a 57% increase from ₹149.37 lakh in Q2 FY26.
Consolidated revenue for Q2 FY27 reached ₹2,892.77 lakh, up 22% YoY from ₹2,370.7
Goldline Pharma H1 Net Profit Rises 44.5% YoY
Board approved unaudited standalone financial results with revenue of ₹14.93 crore and net profit of ₹2.05 crore for H1 FY2026.
Share capital increased to ₹11.41 crore from ₹8.71 crore, indicating a c
Sandu Pharmaceuticals Reports No Fund Utilization Deviations
Sandu Pharmaceuticals filed a regulatory compliance statement confirming no deviation in utilization of ₹5.34 crore raised through three preferential issue tranches.
Funds were raised for revamping ca
Gennex Laboratories Dissolves Rights Issue Committee
Gennex Laboratories' Board dissolved the Rights Issue Committee effective November 14, 2026.
The committee was formed to oversee the company's completed equity rights issue process.
This regulatory di
Aarey Drugs Reports No Fund Utilization Deviation
Aarey Drugs filed a regulatory statement confirming no deviation in utilization of ₹2,481.82 lakhs raised via preferential warrant issue.
The company received ₹1,684.32 lakhs from warrant conversions
Gujarat Themis Biosyn Company Secretary Resignation
Gujarat Themis Biosyn discloses resignation of Company Secretary & Compliance Officer Vineet Gawankar effective November 30, 2026.
Resignation filed under SEBI Listing Regulation 30 with Master Circul
Lasa Supergenerics Q2 FY27 Related Party Disclosures
Lasa Supergenerics discloses related party transactions worth ₹3.33 crore for Q2 and H1 FY27 under SEBI LODR Regulation 23(9).
Transactions include ₹2.43 crore in director remuneration and a ₹2 lakh d
Nutraplus India Q2 FY27 Reports Zero Revenue
Board approved unaudited standalone financial results for Q2 and H1 FY27, reporting zero revenue from operations for both periods.
Company reported a net loss of ₹1.47 lakhs for Q2 FY27 and a net prof
Mercury Laboratories Appoints Sandip Parikh Factory Manager
Mercury Laboratories appointed Mr. Sandip Parikh as Factory Manager (HR) effective November 14, 2026.
The appointment was disclosed pursuant to SEBI Listing Regulations Regulation 30 requirements.
Mr.
Themis Medicare Q2 Net Profit ₹705.72 Lakhs
Board approved Q2 FY27 unaudited standalone and consolidated financial results for period ended 30 September 2026.
Consolidated net profit of ₹705.72 lakhs in Q2 versus loss of ₹361.56 lakhs in Q2 pre
Beryl Drugs Approves Q2 September 2026 Financial Results
Beryl Drugs Ltd's board approved the unaudited financial results for the quarter ended September 30, 2026.
The board meeting was held on November 14, 2026, at the company's registered office in Indore
Astonea Labs H1 FY27 PAT Up 153% YoY
Board approved unaudited standalone and consolidated financial results for H1 FY27, showing revenue of ₹96.21 crore and PAT of ₹4.76 crore.
Approved related party transactions with Longevity Science P
Desh Rakshak Aushdhalaya Reports No Fund Use Deviation
Desh Rakshak Aushdhalaya confirms no deviation in utilization of ₹2.77 crore raised through preferential issue of 12.6 lakh shares.
All raised funds were fully utilized by March 31, 2026 for working c
Fredun Pharmaceuticals Reports No Preferential Fund Deviation
Fredun Pharmaceuticals confirms no deviation in ₹128.78 crore preferential issue proceeds utilization for Q2 FY27.
Monitoring agency CARE Ratings noted reporting discrepancies in fund classification a
Gujarat Themis Q2 Net Profit Drops 18%
Board approved Q2 FY27 unaudited standalone and consolidated financial results, noting a resignation.
Standalone net profit fell 18% YoY to ₹8.47 crore despite a 12% revenue increase.
Company complete
Viyash Scientific Q2 FY27 Earnings Call Recording
Viyash Scientific submitted audio recording of Q2 FY27 earnings call to stock exchanges pursuant to SEBI Regulation 30.
The earnings call was held on November 14, 2026, and recording is available on c
Lactose India Q2 Net Profit Drops 83% YoY
Lactose India reports Q2 FY27 net profit of ₹0.45 crore, down 83% from ₹1.83 crore in Q2 FY26.
Revenue from operations grew 24% YoY to ₹58.19 crore for the quarter ended September 30, 2026.
Company co
Nectar Lifesciences Q2 Net Loss ₹129 Crore
Board approved unaudited standalone and consolidated financial results for Q2 and H1 FY27, reporting a net loss from continuing operations of ₹1,138 lakhs for H1.
Company shifted focus to real estate
Rubicon Research Merger Scheme Returned by MCA
Rubicon Research's fast-track merger application for subsidiary KIA Health Tech was returned by the Regional Director due to insufficient shareholder and creditor approval thresholds.
The company rece
Ravelcare Reports No IPO Fund Utilization Deviation
Ravelcare Limited filed a SEBI Reg. 32(1) disclosure confirming no deviation in IPO fund utilization for H1 FY27.
The company raised ₹24.10 crore in its December 2025 IPO, with ₹13.29 crore utilized a
Parmax Pharma Postpones Q2 FY27 Results Board Meeting
Parmax Pharma postpones its board meeting for Q2 and H1 FY27 unaudited results approval from November 13 to November 14, 2026.
The rescheduled meeting will also consider the shifting of the company's
Gufic Biosciences Assigned 69.7/100 ESG Rating
Gufic Biosciences discloses receipt of an independent ESG rating of 69.7/100 (Medium category) from SES ESG Research for FY 2025-26.
The rating was assigned based on publicly available information wit
Blue Jet Healthcare Signs ₹500 Crore Andhra Pradesh MoU
Blue Jet Healthcare signed non-binding MoU with Andhra Pradesh government for API manufacturing facility investment.
Company plans phased investment of ₹500 crore to acquire 50 acres of land in Andhra
Kopran Clarifies BSE Query on Trading Volume Surge
Kopran Limited responds to BSE surveillance query regarding significant increase in trading volume across exchanges.
Company confirms all material disclosures made per SEBI Listing Regulations Regulat
Vineet Laboratories Reports No Fund Utilization Deviation
Vineet Laboratories Limited filed a regulatory statement confirming no deviation in Rights Issue proceeds utilization for Q2 FY27.
The company raised ₹29.97 crore through a Rights Issue of equity shar
Wanbury Receives ANVISA Approval for Metformin HCl API
Wanbury Limited received regulatory approval (CADIFA) from ANVISA for its flagship API product Metformin HCl EP grade.
This marks the third consecutive ANVISA approval for Wanbury's APIs, enabling cus
Samsrita Labs Reports No Fund Usage Deviation
Samsrita Labs Limited filed a regulatory disclosure confirming no deviation in the use of ₹339.10 lakhs raised through a preferential issue in July 2025.
The company's audit committee reviewed and con
Sun Pharma Advanced Research Volume Increase Clarification
Company confirms compliance with SEBI Listing Regulations in response to exchange query on volume increase.
States all required disclosures under Regulation 30 have been made to the exchanges.
Affirms
Arvaya Healthcare Director Acquires 591,129 Shares Preferentially
Executive Director Bidari Kotresh Anilkumar acquired 591,129 equity shares via preferential allotment on 24 October 2026.
His shareholding increased from 1,720,873 shares (3.58%) to 2,312,002 shares (
Sanofi Healthcare Acquires 15.20% Stake from Hoechst
Sanofi Healthcare India acquired 3.5M shares (15.20%) in Sanofi India from Hoechst GmbH via block deal on Sept 24, 2026.
The inter-se transfer among promoter group members is exempt from open offer un
Sun Pharma Shareholders Approve Promoter Group Reclassification
Sun Pharma shareholders approved reclassification of certain persons from Promoter Group to Public category on 26 September 2026.
The reclassification was conducted under Regulation 31A of SEBI Listin
Indegene Digital Summit 2026 Focuses on AI Operationalization
Indegene Limited hosted its eighth Digital Summit focusing on operationalizing AI investments for measurable business outcomes in life sciences.
The summit featured 200+ industry leaders discussing AI
Astonea Labs Promoter Ashish Gulati Acquires 14,000 Shares
Astonea Labs Ltd files a voluntary disclosure under SEBI Takeover Regulations for promoter Ashish Gulati's acquisition.
Ashish Gulati, a promoter group member, acquired 14,000 equity shares via open m
Granules India Promoter Sells 1.72 Crore Shares
Promoter Dr. Krishna Prasad Chigurupati sold 1.72 crore equity shares via block deal and open market on September 11, 2026.
Transaction proceeds will fund the second tranche of the company's ongoing p
Shree Saibaba Exim Purchases 2.04 Crore Evexia Shares
Evexia Lifecare discloses promoter group entity Shree Saibaba Exim Private Limited purchased 2,03,95,000 equity shares via open market on September 2, 2026.
The acquisition increases Shree Saibaba Exi
Zydus Lifesciences Promoter Group Share Transmission
Zydus Lifesciences discloses off-market transmission of 32,577 shares from late Jasodaben Patel to Prashant Patel.
The disclosure is made under SEBI PIT Regulations regarding promoter group holdings.
Parnax Lab Promoter Acquires 361,872 Shares via Gift
Prakash Shah, a promoter of Parnax Lab, acquired 361,872 equity shares (3.15% stake) from fellow promoter Ila Shah via an off-market gift transfer on July 20, 2026.
The transaction is an inter-se tran